FDA Wants To Review Drug Companies' Posts And Tweets

Law360, New York (January 28, 2014, 5:47 PM EST) -- The U.S. Food and Drug Administration has issued draft guidance addressing some of the unique challenges of drug promotion in the age of social media. Specifically, the draft guidance sheds light on how to comply with the FDA’s post-market submission requirements when interactive promotional media constantly changes. In laying out the criteria for how and when to submit interactive promotional media for post-market review, the FDA gives important insight into the type of social media promotion in which it is most interested; namely, all of it....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.